Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* a healthy male or female, 12-14 months of age at the time of first vaccination, who received at least one dose of pneumococcal conjugate vaccine during study 105553 and with written informed consent obtained from the parent/guardian of the subject.~Exclusion Criteria:~* use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the vaccination, or planned use during the entire study period (active phase and safety follow-up).~* Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before the first dose of vaccine(s) and ending 42-56 days after the last dose of vaccine(s).~* Administration of any additional pneumococcal vaccine since end of study 105553.~* Previous vaccination against measles, mumps, rubella and/or varicella. History of, or intercurrent measles, mumps, rubella and/or varicella/zoster diseases.~* Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to study start.~* Immunosuppressive or immunodeficient condition.~* A history of seizures or neurological disease.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 14 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).